Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Educational Objectives Metastatic Breast Cancer: Scope of the Problem Metastatic Breast Cancer: General Treatment Considerations Therapeutic Goals/Endpoints in MBC MBC: Impact of Chemotherapy Treatment Options for Advanced Breast Cancer First-Line Chemotherapy Options Response Rates with Single-Agent Chemotherapeutic Agents in MBC Highlights of the Evolution of Taxanes in Oncology Taxanes in the Treatment of MBC Conventional Taxanes: Pharmacologic and Pharmacodynamic Differences Conventional Taxanes: Impact of Solvents Albumin Role: Natural Carrier of Hydrophobic Molecules in Humans Increased Intratumoral Concentration With nab-Paclitaxel Differentiating the Taxanes: Toxicity Making Taxanes Less “Tax-ing” Taxane Toxicities Randomized Comparison Between Taxanes Taxanes: Premedication Guidelines Taxane Hypersensitivity Reactions Anemia Differentiating the Taxanes: Efficacy Pivotal Phase III Trials of Paclitaxel Single Agent and Combinations Pivotal Phase III Trials of Docetaxel Single Agent and Combinations TAX 311: Paclitaxel versus Docetaxel in Metastatic Breast Cancer TAX 311: Paclitaxel Versus Docetaxel in Metastatic Breast Cancer – OS TAX 311: Hematologic Toxicity TAX 311: Non-Hematologic Toxicity TAX 311: Quality of Life Analysis Phase III Trial of nab-Paclitaxel vs Paclitaxel in MBC: Design Phase III Trial of nab-Paclitaxel vs Paclitaxel in MBC: Results Phase III Trial of nab-Paclitaxel vs Paclitaxel in MBC: TTP Phase III Trial of nab-Paclitaxel vs Paclitaxel in MBC: OS Phase III Trial of nab-Paclitaxel vs Paclitaxel in MBC: OS ( ≥ 2nd-line Patients) nab-Paclitaxel vs Paclitaxel in MBC: Hematologic Toxicities nab-Paclitaxel vs Paclitaxel in MBC: Non-Hematologic Toxicities nab-Paclitaxel vs Paclitaxel in MBC: Neuropathy Resolution Phase II Study of Weekly nabPaclitaxel in Taxane-Refractory MBC Taxanes: Cost-effectiveness Model Cost-effectiveness Model: Methodology (cont.) Costs per Cycle Frequency of Grade 3/4 Toxicities (O’Shaughnessy 2003) Treatment Costs per Toxicity for Taxane Therapy Cost-effectiveness Ratios Model Analysis of Total Costs Conclusions